- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12:01 | Listing of subscription rights and paid subscription shares of OncoZenge AB | 41 | GlobeNewswire | With effect from September 04, 2026, the subscription rights in OncoZenge AB will be traded on First North Growth Market. Trading will continue up until and including September 15, 2026.
... ► Artikel lesen | |
| Mo | OncoZenge AB: OncoZenge AB advances global patent strategy for BupiZenge with filings in 17 markets | 280 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces that it has entered the national and regional phase of its Patent Cooperation Treaty (PCT) application for BupiZenge in 17 jurisdictions.... ► Artikel lesen | |
| Mo | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.08.2026 | 208 | Xetra Newsboard | Das Instrument 92Y NO0012477704 JACKTEL AS EQUITY wird cum Kapitalmassnahme gehandelt am 31.08.2026 und ex Kapitalmassnahme am 01.09.2026 The instrument 92Y NO0012477704 JACKTEL AS EQUITY is traded... ► Artikel lesen | |
| Fr | OncoZenge AB: Fourth tranche payment deadline expires without full payment from Sichuan Yangtian Bio-Pharmaceutical Co., Ltd | 341 | GlobeNewswire (Europe) | Following the expiry of the payment deadline, OncoZenge AB (publ) ("OncoZenge" or the "Company") provides the following update on the status of the fourth tranche. The extended payment deadline for... ► Artikel lesen | |
| Fr | OncoZenge AB: OncoZenge secures bridge financing of SEK 2.0 million ahead of rights issue | 362 | GlobeNewswire (Europe) | OncoZenge AB (publ) (the "Company" or "OncoZenge") announces today, on 28 August 2026, that the Company has entered into a bridge loan agreement with John Haurum in the amount of SEK 2.0 million in... ► Artikel lesen | |
| 27.08. | OncoZenge AB: Investor withholds remaining payment for fourth tranche resulting in short-term liquidity shortfall | 107 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or the "Company") has received a letter from Sichuan Yangtian Bio-Pharmaceutical Co., Ltd (the "Investor") with information that the Investor will withhold payment of... ► Artikel lesen | |
| 27.08. | OncoZenge AB: OncoZenge AB Interim Report January 1 - June 30, 2026 | 131 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced the interim report for the second quarter of 2026. The company reports receipt of regulatory approval to initiate patient recruitment... ► Artikel lesen | |
| ONCOZENGE Aktie jetzt für 0€ handeln | |||||
| 25.08. | OncoZenge AB: OncoZenge resolves on a rights issue of approximately SEK 33.3 million and publishes preliminary financial information for the second quarter of 2026 | 459 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND... ► Artikel lesen | |
| 07.08. | OncoZenge AB: OncoZenge Extends the Payment Deadline for Remaining Subscription Proceeds | 403 | GlobeNewswire (Europe) | The Board of Directors of OncoZenge AB (publ) ("OncoZenge" or "the Company") has resolved to extend the payment deadline for payment of the remaining subscription proceeds of approximately SEK 10.1... ► Artikel lesen | |
| 17.07. | OncoZenge AB: OncoZenge Extends the Payment Deadline for Remaining Subscription Proceeds | 315 | GlobeNewswire (Europe) | The Board of Directors of OncoZenge AB (publ) ("OncoZenge" or "the Company") has resolved to extend the payment deadline for payment of the remaining subscription proceeds of approximately SEK 10.1... ► Artikel lesen | |
| 07.07. | OncoZenge AB: OncoZenge AB Announces Enrollment of First Patient in Pivotal Phase III BEAM-Pain Trial of BupiZenge | 1.100 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company"), a clinical-stage company developing an innovative treatment for oral pain in cancer supportive care, today announces that the first patient has been... ► Artikel lesen | |
| 03.07. | OncoZenge AB: OncoZenge Extends the Payment Deadline for Subscription Proceeds | 303 | GlobeNewswire (Europe) | The Board of Directors of OncoZenge AB (publ) ("OncoZenge" or "the Company") has resolved to extend the payment deadline for payment of the subscription proceeds of approximately SEK 15.1 million in... ► Artikel lesen | |
| 02.06. | OncoZenge AB: OncoZenge Receives CTA Approval Milestone Payment From Molteni Farmaceutici | 222 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces that the second milestone payment has been received from the Company's licensee, Molteni Farmaceutici.
The company announced on March... ► Artikel lesen | |
| 27.05. | OncoZenge AB: Bulletin From The Annual General Meeting Of OncoZenge | 215 | GlobeNewswire (Europe) | At the annual general meeting ("AGM") of OncoZenge AB (publ) held on 27 May 2026, the following principal resolutions were adopted, in accordance with the proposals submitted by the Board of Directors... ► Artikel lesen | |
| 26.05. | OncoZenge AB: OncoZenge Receives European Regulatory Approval to Start Pivotal Phase III Trial of BupiZenge | 760 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company"), a clinical-stage company developing an innovative treatment for oral pain in cancer supportive care, today announced that it has received regulatory... ► Artikel lesen | |
| 26.05. | OncoZenge AB: OncoZenge AB Interim Report January 1 - March 31, 2026 | 235 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announced the interim report for the first quarter of 2026. The company reports progress with European authorities expecting regulatory approval... ► Artikel lesen | |
| 22.05. | OncoZenge AB: OncoZenge enters into a loan agreement of SEK 2 million with Linc AB | 177 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") has today entered into an agreement regarding bridge financing of SEK 2 million through a loan provided by one of the Company's largest shareholders... ► Artikel lesen | |
| 19.05. | OncoZenge AB: OncoZenge Provides Regulatory Update on BupiZenge Phase III Trial | 266 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces that it has received written notification from European authorities regarding the ongoing assessment of its Clinical Trial Application... ► Artikel lesen | |
| 28.04. | OncoZenge AB: OncoZenge Receives Conditional Acceptance for the Clinical Phase III Trial ('BEAM-Pain') of BupiZenge from European Authorities | 607 | GlobeNewswire (Europe) | OncoZenge AB (publ) ("OncoZenge" or "the Company"), a clinical-stage company developing an innovative treatment for oral pain in cancer supportive care, today announces that it has received conditional... ► Artikel lesen | |
| 02.04. | OncoZenge AB: OncoZenge Confirms Submission of Responses to EMA on the BupiZenge Phase III Trial (BZ003) | 159 | GlobeNewswire (Europe) | OncoZenge AB (publ), OncoZenge or "the Company", developing innovative treatments for oral pain management, today announced the complete submission of responses to European authorities' Requests for... ► Artikel lesen |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 41,350 | +2,52 % | ANALYSE-FLASH: Deutsche Bank senkt Novo Nordisk auf 'Sell' - Ziel 265 Kronen | FRANKFURT (dpa-AFX Broker) - Deutsche Bank Research hat das Kursziel für Novo Nordisk von 290 auf 265 dänische Kronen gesenkt und die Aktien von "Hold" auf "Sell" abgestuft. Die zu Anfang des Monats... ► Artikel lesen | |
| ASTRAZENECA | 142,55 | +2,19 % | Astrazeneca-Medikament Tezspire erreicht Studienziel bei Ösophagitis | DJ Astrazeneca-Medikament Tezspire erreicht Studienziel bei Ösophagitis
Von Michael Hennessey
DOW JONES--Astrazeneca hat einen Studienerfolg mit dem Medikament Tezspire verbucht. Wie der britische... ► Artikel lesen | |
| CAMURUS | 54,05 | +1,41 % | Camurus AB: Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA | PDUFA target action date set to 18 December 2026LUND, Sweden, July 17, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Administration (FDA) has accepted... ► Artikel lesen | |
| BAYER | 49,720 | +1,10 % | MARKET TALK/US-Gericht weist Antrag auf Verlegung von Bayer-Glyphosat-Vergleich ab | DJ MARKET TALK/US-Gericht weist Antrag auf Verlegung von Bayer-Glyphosat-Vergleich ab
Kläger gegen den Bayer-Konzern in den USA sind in der Berufungsinstanz mit dem Versuch gescheitert, die Zuständigkeit... ► Artikel lesen | |
| MERCK KGAA | 140,20 | +0,14 % | Aktien Frankfurt Ausblick: Dax knapp im Minus - Rutsch unter 21-Tage-Linie | FRANKFURT (dpa-AFX) - Für den Dax zeichnen sich nach dem schwachen Wochenauftakt am Dienstag weitere moderate Verluste ab. Eine Stunde vor Handelsbeginn signalisierte der X-Dax als außerbörslicher... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 61,96 | 0,00 % | PAUL MAIER V At Eton Pharmaceuticals Executes Options Exercise, Realizing $2.84M | ||
| LB PHARMACEUTICALS | 49,420 | 0,00 % | LB Pharmaceuticals appoints Joseph Miller as CFO | ||
| GENERATE BIOMEDICINES | 16,260 | -0,12 % | Generate Biomedicines stock price target raised to $30 by H.C. Wainwright on asthma data | ||
| APNIMED | 27,830 | 0,00 % | Apnimed, Inc.: Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares | CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization... ► Artikel lesen | |
| PFIZER | 24,905 | -0,54 % | Gewinner der Börsengeschichte: Kaum ein Deutscher kennt diese Heißzeit-Aktie - Sie brachte +3.923.693% Rendite! | © Foto: Christoph Hardt/Geisler-Fotopress - Geisler-FotopressDer US-amerikanische Anbieter von Klimalösungen Trane Technologies gilt als Profiteur des Klimawandels. Die Buy-and-Hold-Gesamtrendite liegt... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 5,380 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Successfully completed human factors validation study and pharmacokinetic study for Anaphylm (dibutepinephrine) sublingual filmRemains on track to resubmit Anaphylm NDA to the FDA in Q3 2026Continues... ► Artikel lesen | |
| KARDIGAN | 21,820 | -0,46 % | Citi's U.S. Consumer Cards Business To Buy Kard Financial For Undisclosed Terms | WASHINGTON (dpa-AFX) - Banking major Citigroup Inc. (C) announced late Thursday that its U.S. Consumer Cards business has agreed to acquire Kard Financial, a commerce media and rewards platform.... ► Artikel lesen | |
| UNIVERSE PHARMACEUTICALS | 4,740 | -0,63 % | 6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More | BEIJING (dpa-AFX) - Today's after-hours gainers in the healthcare sector included Universe Pharmaceuticals, which drew attention after disclosing multiple Schedule 13G filings; bioAffinity Technologies... ► Artikel lesen | |
| ATRIUM THERAPEUTICS | 14,060 | 0,00 % | Atrium Therapeutics Reports Second Quarter 2026 Financial Results | -- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome --
-- Achieved second milestone payment under global cardiovascular collaboration... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 12,590 | -0,16 % | Kazia Therapeutics Limited: Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy | Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further... ► Artikel lesen |
Das Unternehmen ONCOZENGE AB kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,023 (+6,55 %) liegt der Kurs bei 0,366 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONCOZENGE AB finden Sie auf Wallstreet Online.